NCT03869476Completed
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis
Source: ClinicalTrials.gov · Last updated 30 Dec 2024
Brief summary (registry, in English)
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 133 (actual)
- First submitted
- 6 Mar 2019
- Start date
- Jul 2019
- Primary completion date
- Jan 2024
- Lead sponsor
- University Hospital, Angers
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT03869476
What you commit to
- Study type: Interventional
- Participants enrolled: 133
- From Jul 2019 to the primary completion date, Jan 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis;
Other
- Patient with a diagnosis of secondary myelofibrosis;
- Pregnant or breastfeeding woman;
- Person prived of liberty by judicial or administrative decision;
- Person subject to a legal protection measure;
Who the study is looking for
- Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria;
- Patient who has not received specific treatment for neoplasms;
- Patient who has signed the consent to participate in the study;
- Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Angers Coordinator of this site? Confirm its status | Angers | France | Unknown status |
| CHRU de Brest - Hôpital Morvan Coordinator of this site? Confirm its status | Brest | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.